Abstract
The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Current Molecular Medicine
Title: The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis
Volume: 8 Issue: 2
Author(s): Kerstin Reimers, Claudia Y.U. Choi, Vesna Bucan and Peter M. Vogt
Affiliation:
Keywords: Protein family, Bax-inhibitor, programmed cell death, apoptosis inhibitors, transmembrane protein, cancer
Abstract: The signaling pathways that determine the fate of a cell regarding death or survival depend on a large number of regulatory proteins. The Bax Inhibitor-1 (BI-1) family is a highly preserved family of small transmembrane proteins located mostly in the endoplasmic reticulum (ER). Although most members of this family are still not characterized an antiapoptotic effect has been described for BI-1, Lifeguard (LFG), and the Golgi anti-apoptotic protein (GAAP). The cytoprotective activity has been associated to the control of ion homeostasis and ER stress but includes other cell death stimuli as well. Recent data describes multiple interactions between the proteins of the BI-1 family and the Bcl-2 family either stimulating the antiapoptotic function of Bcl-2 or inhibiting the proapoptotic effect of Bax. The potent cell death suppression makes this protein family an interesting target for the development of new drugs and gene therapeutic approaches for diseases caused by apoptotic dysregulation, such as cancer.
Export Options
About this article
Cite this article as:
Reimers Kerstin, Choi Y.U. Claudia, Bucan Vesna and Vogt M. Peter, The Bax Inhibitor-1 (BI-1) Family in Apoptosis and Tumorigenesis, Current Molecular Medicine 2008; 8 (2) . https://dx.doi.org/10.2174/156652408783769562
DOI https://dx.doi.org/10.2174/156652408783769562 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Immunotherapy for Prostate Cancer
Current Pharmaceutical Design The Role of a Human Hematopoietic Mesenchymal Progenitor in Wound Healing and Fibrotic Diseases and Implications for Therapy
Current Stem Cell Research & Therapy Anti-Cancer Compounds from Terrestrial and Marine Resources -In silico and Experimental Studies
Current Computer-Aided Drug Design Targeting Cancer Stem Cells with Repurposed Drugs to Improve Current Therapies
Recent Patents on Anti-Cancer Drug Discovery A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Celastrol Inhibits the Proliferation and Decreases Drug Resistance of Cisplatin- Resistant Gastric Cancer SGC7901/DDP Cells
Anti-Cancer Agents in Medicinal Chemistry The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Current and Future Clinical Strategies in Colon Cancer Prevention and the Emerging Role of Chemoprevention
Current Pharmaceutical Design Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Lipid Metabolism and Mitochondria: Cross Talk in Cancer
Current Drug Targets Ubiquitination in Rho Signaling
Current Topics in Medicinal Chemistry Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery The Impact of Combination Therapy with a-Blockers and 5ARIs on the Progression of BPH
Current Drug Targets Determinants of Anti-Cancer Effect of Mitochondrial Electron Transport Chain Inhibitors: Bioenergetic Profile and Metabolic Flexibility of Cancer Cells
Current Pharmaceutical Design Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Sentinel Lymph Node Mapping in Early Stage Endometrial Cancer Patients in Low-Resource Settings
Current Women`s Health Reviews Pharmaceutical Strategies Enhancing Cell Penetration Efficiencies of Non-Viral Gene Delivery Systems
Current Gene Therapy